Brief: Cocrystal Pharma Reports First Quarter 2023 Financial Results And Provides Updates On Its Antiviral Drug Development Programs
15/05/2023 13:15
Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES UPDATES ON ITS ANTIVIRAL DRUG DEVELOPMENT PROGRAMS
* COCRYSTAL PHARMA INC QTRLY NET LOSS PER COMMON SHARE,
BASIC AND
DILUTED $0.64
Source text for Eikon: ID:nGNX67G9bR
Further company coverage: COCP.O
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway